Last-Resort drug access for severe colitis patients
NCT ID NCT06025227
First seen Nov 18, 2025 · Last updated May 11, 2026 · Updated 21 times
Summary
This program offers early access to the drug etrasimod for people with ulcerative colitis who have not improved with at least three other treatments. It is designed for individual patients with no other options. The goal is to help control the disease when standard therapies have failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.